Merck & Co., Inc. Stock

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-17 pm EDT 5-day change 1st Jan Change
125.4 USD +0.25% Intraday chart for Merck & Co., Inc. -1.09% +15.00%
Sales 2024 * 63.78B Sales 2025 * 68.02B Capitalization 318B
Net income 2024 * 19.51B Net income 2025 * 21.75B EV / Sales 2024 * 5.29 x
Net Debt 2024 * 19.65B Net Debt 2025 * 7.53B EV / Sales 2025 * 4.78 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
14.1 x
Employees 71,000
Yield 2024 *
2.44%
Yield 2025 *
2.58%
Free-Float 70.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.25%
1 week-1.09%
Current month-4.99%
1 month+3.17%
3 months+6.13%
6 months+20.35%
Current year+15.00%
More quotes
1 week
124.71
Extreme 124.71
127.82
1 month
120.38
Extreme 120.38
133.10
Current year
109.16
Extreme 109.16
133.10
1 year
99.14
Extreme 99.14
133.10
3 years
70.89
Extreme 70.89
133.10
5 years
65.25
Extreme 65.25
133.10
10 years
45.69
Extreme 45.69
133.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-04-17 125.4 +0.25% 6,122,908
24-04-16 125.1 -0.90% 5,587,332
24-04-15 126.2 +0.36% 6,241,069
24-04-12 125.7 -0.33% 7,369,989
24-04-11 126.2 -0.47% 6,187,364

Delayed Quote Nyse, April 17, 2024 at 04:00 pm EDT

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
125.4 USD
Average target price
137.2 USD
Spread / Average Target
+9.41%
Consensus